STME — StimCell Enegetics Share Price
0.000.00%
Last trade - 00:00- $7.73m
- $8.11m
- 15
- 45
- 42
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st May | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.1 | 0.01 | 0.01 | 0 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
StimCell Enegetics Inc., formerly Cell MedX Corp., is a development stage electroceutical medical device company. The Company’s products include eBalance, and Bio Feedback. The eBalance is a non-invasive, fully automated microcurrent electrotherapy system administering pre-programmed algorithms. The biofeedback mechanism is where eBalance offering users and health professionals alike a real-time snapshot of cellular vitality. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling. Microcurrent is a clinically tested therapy treatment used to treat a range of conditions. There is compelling research in diabetes care, wound therapy, migraine treatment, chronic obstructive pulmonary disease (COPD), and anti-ageing.
Directors
- Frank Mcenulty CEO (64)
- Yanika Silina CFO (43)
- Joao Da Costa COO (57)
- Bradley Hargreaves VOP (62)
- George Adams IND (70)
- Last Annual
- May 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- March 19th, 2010
- Public Since
- March 11th, 2013
- No. of Shareholders
- 62
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 19,816,272
- Address
- 820 - 1130 West Pender Street, VANCOUVER, V6E 4A4
- Web
- https://stimcell.com/
- Phone
- +1 3105089398
- Auditors
- DALE MATHESON CARR-HILTON LABONTE LLP
Upcoming Events for STME
Q1 2026 Cell MedX Corp Earnings Release
Similar to STME
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the StimCell Enegetics share price?
As of Today at 23:27 UTC, shares in StimCell Enegetics are trading at $0.39. This share price information is delayed by 15 minutes.
How has the StimCell Enegetics share price performed this year?
Shares in StimCell Enegetics last closed at $0.39 and the price had moved by +18.15% over the past 365 days. In terms of relative price strength the StimCell Enegetics share price has outperformed the S&P500 Index by +9.56% over the past year.
What are the analyst and broker recommendations for StimCell Enegetics?
There is no consensus recommendation for this security.
Find out moreWhat is the StimCell Enegetics dividend yield?
StimCell Enegetics does not currently pay a dividend.
Does StimCell Enegetics pay a dividend?
StimCell Enegetics does not currently pay a dividend.
When does StimCell Enegetics next pay dividends?
StimCell Enegetics does not currently pay a dividend.
How do I buy StimCell Enegetics shares?
To buy shares in StimCell Enegetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of StimCell Enegetics?
As of the previous close price of $0.39, shares in StimCell Enegetics had a market capitalisation of $7.73m.
Where are StimCell Enegetics shares listed?
Here are the trading details for StimCell Enegetics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: STME
What kind of share is StimCell Enegetics?
Based on an overall assessment of its quality, value and momentum StimCell Enegetics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a StimCell Enegetics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the StimCell Enegetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like StimCell Enegetics. Over the past six months, its share price has underperformed the S&P500 Index by -9.51%.
As of the last closing price of $0.39, shares in StimCell Enegetics were trading -1.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the StimCell Enegetics PE Ratio?
The StimCell Enegetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of StimCell Enegetics?
StimCell Enegetics' management team is headed by:
- Frank Mcenulty - CEO
- Yanika Silina - CFO
- Joao Da Costa - COO
- Bradley Hargreaves - VOP
- George Adams - IND